Pacific Biosciences of California Cash Flow Conversion Efficiency
Pacific Biosciences of California cash flow conversion efficiency. Based on the latest financial reports, Pacific Biosciences of California (PACB) has a cash flow conversion efficiency ratio of 2.417x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-80.27 Million) by net assets ($-33.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pacific Biosciences of California (2008–2025)
Cash flow conversion efficiency of Pacific Biosciences of California from 2008 to 2025. This chart illustrates how Pacific Biosciences of California's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pacific Biosciences of California share price for real-time trading data and today's change.
Pacific Biosciences of California Cash Flow Conversion Ratio Explained
Pacific Biosciences of California cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pacific Biosciences of California Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacific Biosciences of California ranked by their cash flow conversion efficiency. Also see Pacific Biosciences of California market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bassac
PA:BASS
|
-0.009x |
|
Yuanli Chemical Group Co Ltd
SHG:603217
|
-0.001x |
|
engcon AB Cl B
ST:ENGCON-B
|
0.079x |
|
WAVE LIFE SCIENCES LTD.
F:1U5
|
-0.116x |
|
Himalaya Shipping Ltd.
NYSE:HSHP
|
0.063x |
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
0.059x |
|
CRH PLC
LSE:CRH
|
-0.025x |
|
Vina Concha To
SN:CONCHATORO
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Pacific Biosciences of California (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacific Biosciences of California from 2008 to 2025. Review Pacific Biosciences of California free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.35 Million | $-111.21 Million | -20.791x | -5011.38% |
| 2024-12-31 | $506.59 Million | $-206.06 Million | -0.407x | -7.02% |
| 2023-12-31 | $701.30 Million | $-266.55 Million | -0.380x | +18.72% |
| 2022-12-31 | $562.90 Million | $-263.21 Million | -0.468x | -232.67% |
| 2021-12-31 | $790.99 Million | $-111.18 Million | -0.141x | -341.79% |
| 2020-12-31 | $335.49 Million | $19.50 Million | 0.058x | +104.08% |
| 2019-12-31 | $54.92 Million | $-78.31 Million | -1.426x | -144.85% |
| 2018-12-31 | $114.06 Million | $-66.43 Million | -0.582x | +25.73% |
| 2017-12-31 | $86.10 Million | $-67.52 Million | -0.784x | +2.26% |
| 2016-12-31 | $84.67 Million | $-67.93 Million | -0.802x | -23.20% |
| 2015-12-31 | $73.54 Million | $-47.89 Million | -0.651x | +30.48% |
| 2014-12-31 | $54.95 Million | $-51.47 Million | -0.937x | -117.20% |
| 2013-12-31 | $69.18 Million | $-29.83 Million | -0.431x | +38.60% |
| 2012-12-31 | $109.38 Million | $-76.82 Million | -0.702x | -30.59% |
| 2011-12-31 | $191.46 Million | $-102.97 Million | -0.538x | -23.38% |
| 2010-12-31 | $279.87 Million | $-122.00 Million | -0.436x | -203.17% |
| 2009-12-31 | $-177.12 Million | $-74.84 Million | 0.423x | +3.02% |
| 2008-12-31 | $-93.39 Million | $-38.30 Million | 0.410x | -- |
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more